Which came first, MHC class I or MHC class II? For decades, it has been debated which of these two similar classes came first in evolution. Now, Keiichiro Hashimoto and his group at Fujita Health ...

Recombinant human leukocyte antigen class II histocompatibility antigen (HLA-DRA) has been implicated in the development of various cancers, but its specific role in clear cell renal cell carcinoma ...

Square-planar, four-coordinate metal complexes strip peptides from the binding site of MHC class II molecules. Removal of peptides derived from self-antigens could prevent class II–dependent ...

A new study sheds light on why some patients with the most aggressive form of ovarian cancer respond better to treatment than others. Tumors positive for a molecule called MHC class II are linked to ...

While previous research has proven the role of MHC-I molecules, a new study in Cell suggests that MHC-II may also serve as a target in immunotherapy. Patient-specific variations in MHC-II molecules ...

The study, according to the researchers, is the first to demonstrate the potential use of major histocompatibility complex class II (MHC-II) expression as a predictor of immunotherapy response in ...

Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...

This project is scheduled to run from September 2026 to March 2029. It will serve as a drug discovery use case for applying quantum computing technology and AI to design and optimize neoantigen ...

Which came first, MHC class I or MHC class II? For decades, it has been debated which of these two similar classes came first in evolution. Now, Keiichiro Hashimoto and his group at Fujita Health ...

Newswise — Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse ...